Verastem

Press Releases

August 1, 2019
Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress
July 29, 2019
Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer
July 25, 2019
Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development and Commercialization of COPIKTRA® (duvelisib) in Russia and CIS, Turkey, the Middle East and Africa
July 25, 2019
Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019
July 3, 2019
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 21, 2019
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on Malignant Lymphoma
June 20, 2019
Verastem Oncology Announces Leadership Changes
June 17, 2019
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting
May 30, 2019
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference
May 16, 2019
Verastem Oncology to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
May 15, 2019
Verastem Oncology to Present New COPIKTRA™ (Duvelisib) Dose Modification Data from Patients Treated in the Phase 3 DUO Study
May 9, 2019
Verastem Oncology Reports First Quarter 2019 Financial Results
May 2, 2019
Verastem Oncology to Announce First Quarter 2019 Financial Results and Corporate Update on May 9, 2019
April 23, 2019
Verastem Oncology Announces Amendment to Refinance Hercules Loan Facility
April 4, 2019
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 2, 2019
Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
March 12, 2019
Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments
March 12, 2019
Verastem Oncology to Present at Upcoming Investor Conferences
March 7, 2019
Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Malignancies
March 4, 2019
Verastem Oncology Presents Phase 3 DUO™ Data Evaluating COPIKTRA™ (Duvelisib) in Patients with CLL/SLL Who Have Progressed Following Two Prior Lines of Therapy
March 1, 2019
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 26, 2019
Verastem Oncology to Announce Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update on March 12, 2019
February 21, 2019
Verastem Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference
February 20, 2019
Verastem Oncology Announces Key Management Appointments
February 14, 2019
Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology
February 4, 2019
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 7, 2019
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 3, 2019
Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress
January 3, 2019
Verastem Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

E-mail Alerts

You may automatically receive Verastem Oncology financial information by e-mail. To choose your options for e-mail notification, please enter your e-mail address below and click Submit.

Investor Contact

getty
John Doyle

VP Investor Relations & Finance
781.292.4279
jdoyle@verastem.com

Joe Rayne

Argot Partners
617.340.6075
joseph@argotpartners.com

Investor Kit